Literature DB >> 17070434

Medication adherence and persistence as the cornerstone of effective antihypertensive therapy.

Michel Burnier1.   

Abstract

Achieving optimal outcomes in the treatment of hypertension--a prevalent and largely asymptomatic disease--necessitates that patients take their medications not only properly (medication adherence) but also continue to do so throughout long-term treatment (persistence). However, poor medication-taking behavior is a major problem among patients with hypertension, and has been identified as one of the main causes of failure to achieve adequate control of blood pressure (BP). In turn, patients with hypertension who have uncontrolled BP as a result of their poor medication-taking behavior remain at risk for serious morbidity and mortality (eg, stroke, myocardial infarction, and kidney failure), thereby accounting for a significant cost burden through avoidable hospital admissions, premature deaths, work absenteeism, and reduced productivity. Improving medication-taking behavior during antihypertensive therapy therefore represents an important potential source of health and economic improvement. Whereas many factors may contribute to poor medication-taking behavior, the complexity of dosage regimens and the side effect profiles of drugs probably have the greatest therapy-related influence. Central to any strategy aimed at improving outcomes for patients with hypertension, therefore, are efficacious antihypertensive agents that facilitate good medication-taking behavior through simplified dosing and placebo-like tolerability, along with the development of programs to detect poor medication adherence and to support long-term medication persistence in daily practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070434     DOI: 10.1016/j.amjhyper.2006.04.006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  91 in total

1.  Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.

Authors:  Yuichi Tasaka; Daiki Yasunaga; Mamoru Tanaka; Akihiro Tanaka; Takashige Asakawa; Ikuo Horio; Yoshiro Miyauchi; Hiroaki Araki
Journal:  Int J Clin Pharm       Date:  2016-01-08

2.  Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012.

Authors:  Gabriel S Tajeu; Shia T Kent; Ian M Kronish; Lei Huang; Marie Krousel-Wood; Adam P Bress; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

3.  Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapy.

Authors:  Sung W Rhee; Joseph R Stimers; Wenze Wang; Li Pang
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

4.  Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies.

Authors:  Steen Neldam; Colin Edwards; Margreet Lang; Russell Jones
Journal:  Curr Ther Res Clin Exp       Date:  2012-02

Review 5.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.

Authors:  Bora Youn; Theresa I Shireman; Yoojin Lee; Omar Galárraga; Aadia I Rana; Amy C Justice; Ira B Wilson
Journal:  AIDS       Date:  2017-07-31       Impact factor: 4.177

7.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

8.  Do psychological attributes matter for adherence to antihypertensive medication? The Finnish Public Sector Cohort Study.

Authors:  Hermann Nabi; Jussi Vahtera; Archana Singh-Manoux; Jaana Pentti; Tuula Oksanen; David Gimeno; Marko Elovainio; Marianna Virtanen; Timo Klaukka; Mika Kivimaki
Journal:  J Hypertens       Date:  2008-11       Impact factor: 4.844

9.  Screening, treatment, and control of hypertension in US private physician offices, 2003-2004.

Authors:  Jun Ma; Randall S Stafford
Journal:  Hypertension       Date:  2008-03-17       Impact factor: 10.190

10.  The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants.

Authors:  K A Payne; J J Caro; W L Daley; Z M Khan; K J Ishak; K Stark; D Purkayastha; J Flack; E Velázquez; S Nesbitt; D Morisky; R Califf
Journal:  Int J Clin Pract       Date:  2008-07-21       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.